NextCure, Inc. (NXTC)

Compare

0.3901

-0.0069

(-1.74%)

At close: April 4 at 4:00:02 PM EDT

0.4019

+0.01

+(3.02%)

After hours: April 4 at 7:25:13 PM EDT

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the we

GlobeNewswire yesterday

NXTC
-1.74%
NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today prov

GlobeNewswire 30 days ago

NXTC
-1.74%
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. last month

NXTC
-1.74%
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. “Dosing the first patient in the LNCB74 Phase 1 study is a significant milestone for NextC

GlobeNewswire 2 months ago

NXTC
-1.74%
NextCure Announces Acceptance of IND Application for LNCB74

LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of

GlobeNewswire 3 months ago

NXTC
-1.74%
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website a

GlobeNewswire 4 months ago

NXTC
-1.74%
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfec

GlobeNewswire 4 months ago

NXTC
-1.74%
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results. “T

GlobeNewswire 4 months ago

NXTC
-1.74%
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-endAdditional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today repor

GlobeNewswire 4 months ago

NXTC
-1.74%
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with p

GlobeNewswire 5 months ago

NXTC
-1.74%
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phas

GlobeNewswire 6 months ago

NXTC
-1.74%
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 6 months ago

NXTC
-1.74%
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a busi

GlobeNewswire 7 months ago

NXTC
-1.74%
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024. A recording of the webcast will be available on the conference day starting at 7 AM ET through the Investo

GlobeNewswire 9 months ago

NXTC
-1.74%
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43%Data to be presented June 1, 2024, 9:00 am-12:00 pm CT BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class the

GlobeNewswire 10 months ago

NXTC
-1.74%
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today pr

GlobeNewswire 10 months ago

NXTC
-1.74%
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in com

GlobeNewswire 11 months ago

NXTC
-1.74%
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly

GlobeNewswire 11 months ago

NXTC
-1.74%

Performance Overview

Return	NXTC	S&P 500 (^GSPC)
YTD	-49.40%	-13.73%
1-Year	-81.94%	-1.42%
3-Year	-92.26%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NextCure, Inc. (NXTC)

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Announces Acceptance of IND Application for LNCB74

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Performance Overview